The latest price target for AbCellera Biologics (NASDAQ:ABCL) was reported by Benchmark on November 5, 2024. The analyst firm set a price target for $0.00 expecting ABCL to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ:ABCL) was provided by Benchmark, and AbCellera Biologics reiterated their hold rating.

The last upgrade for AbCellera Biologics Inc happened on February 22, 2024 when Benchmark raised their price target to N/A. Benchmark previously had a hold for AbCellera Biologics Inc.

The last downgrade for AbCellera Biologics Inc happened on August 20, 2024 when Benchmark changed their price target from N/A to N/A for AbCellera Biologics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on November 5, 2024 so you should expect the next rating to be made available sometime around November 5, 2025.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a reiterated with a price target of $0.00 to $0.00. The current price AbCellera Biologics (ABCL) is trading at is $2.80, which is out of the analyst’s predicted range.